$43.49
0.050.12%
Last update: 10:27 AM
15 minutes delayed
Comments
Loading...
Cerevel Therapeutics Hldg
CERENASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Cerevel Therapeutics Hldg (NASDAQ:CERE) Stock, Analyst Ratings, Price Targets, Forecasts
Cerevel Therapeutics Holdings Inc has a consensus price target of $40.67 based on the ratings of 16 analysts. The high is $54 issued by Stifel on August 9, 2022. The low is $22 issued by Berenberg on March 16, 2023. The 3 most-recent analyst ratings were released by Mizuho, JP Morgan, and Jefferies on February 16, 2024, December 28, 2023, and December 22, 2023, respectively. With an average price target of $45 between Mizuho, JP Morgan, and Jefferies, there's an implied 3.47% upside for Cerevel Therapeutics Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
JP Morgan
Jefferies
TD Cowen
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Cerevel Therapeutics Hldg
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/16/2024 | Buy Now | 3.47% | Mizuho | Graig Suvannavejh | $25 → $45 | Maintains | Neutral | Get Alert |
| 12/28/2023 | Buy Now | 3.47% | JP Morgan | Jessica Fye | $25 → $45 | Maintains | Neutral | Get Alert |
| 12/22/2023 | Buy Now | 3.47% | Jefferies | Michael Yee | $40 → $45 | Downgrade | Buy → Hold | Get Alert |
| 12/08/2023 | Buy Now | 3.47% | TD Cowen | Joseph Thome | → $45 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/07/2023 | Buy Now | 3.47% | HC Wainwright & Co. | Douglas Tsao | $41 → $45 | Downgrade | Buy → Neutral | Get Alert |
| 12/07/2023 | Buy Now | 3.47% | Piper Sandler | David Amsellem | $33 → $45 | Downgrade | Overweight → Neutral | Get Alert |
| 12/07/2023 | Buy Now | 3.47% | Cantor Fitzgerald | Charles Duncan | $38 → $45 | Downgrade | Overweight → Neutral | Get Alert |
| 11/20/2023 | Buy Now | -42.52% | JP Morgan | Jessica Fye | → $25 | Reinstates | → Neutral | Get Alert |
| 11/02/2023 | Buy Now | -12.62% | Morgan Stanley | Matthew Harrison | $42 → $38 | Maintains | Overweight | Get Alert |
| 09/28/2023 | Buy Now | -24.12% | Piper Sandler | David Amsellem | → $33 | Initiates | → Overweight | Get Alert |
| 08/07/2023 | Buy Now | -42.52% | Mizuho | Graig Suvannavejh | $29 → $25 | Maintains | Neutral | Get Alert |
| 08/03/2023 | Buy Now | -3.43% | Morgan Stanley | Matthew Harrison | $46 → $42 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -28.72% | B of A Securities | Tazeen Ahmad | $36 → $31 | Downgrade | Buy → Neutral | Get Alert |
| 08/03/2023 | Buy Now | -5.73% | HC Wainwright & Co. | Douglas Tsao | $45 → $41 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -31.02% | Goldman Sachs | Madhu Kumar | $31 → $30 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | -33.32% | Mizuho | Graig Suvannavejh | $26 → $29 | Maintains | Neutral | Get Alert |
| 05/04/2023 | Buy Now | -31.02% | Wells Fargo | Mohit Bansal | → $30 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/10/2023 | Buy Now | — | TD Cowen | Joseph Thome | — | Initiates | → Outperform | Get Alert |
| 04/03/2023 | Buy Now | 3.47% | HC Wainwright & Co. | Douglas Tsao | → $45 | Reiterates | → Buy | Get Alert |
| 03/17/2023 | Buy Now | -33.32% | JP Morgan | Jessica Fye | $40 → $29 | Downgrade | Overweight → Neutral | Get Alert |
| 03/16/2023 | Buy Now | -49.41% | Berenberg | Caroline Palomeque | → $22 | Reinstates | → Hold | Get Alert |
| 03/09/2023 | Buy Now | -40.22% | Mizuho | Graig Suvannavejh | $28 → $26 | Maintains | Neutral | Get Alert |
| 02/23/2023 | Buy Now | -8.02% | Morgan Stanley | Matthew Harrison | $50 → $40 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 3.47% | HC Wainwright & Co. | Douglas Tsao | $48 → $45 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | -31.02% | Wells Fargo | Mohit Bansal | $38 → $30 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/22/2023 | Buy Now | -28.72% | Goldman Sachs | Madhu Kumar | $28 → $31 | Maintains | Neutral | Get Alert |
| 12/06/2022 | Buy Now | -8.02% | JP Morgan | Jessica Fye | $49 → $40 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | -35.62% | Mizuho | Graig Suvannavejh | $32 → $28 | Maintains | Neutral | Get Alert |
| 11/09/2022 | Buy Now | 10.37% | HC Wainwright & Co. | Douglas Tsao | $50 → $48 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | -8.02% | Loop Capital | Esther Hong | → $40 | Initiates | → Buy | Get Alert |
| 10/20/2022 | Buy Now | -10.32% | B of A Securities | Tazeen Ahmad | → $39 | Initiates | → Buy | Get Alert |
| 09/29/2022 | Buy Now | -5.73% | Cantor Fitzgerald | Charles Duncan | → $41 | Initiates | → Overweight | Get Alert |
| 09/26/2022 | Buy Now | -12.62% | Wells Fargo | Mohit Bansal | → $38 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | Buy Now | -35.62% | Goldman Sachs | Madhu Kumar | $24 → $28 | Maintains | Neutral | Get Alert |
| 09/13/2022 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 08/23/2022 | Buy Now | -26.42% | Mizuho | Graig Suvannavejh | $27 → $32 | Maintains | Neutral | Get Alert |
| 08/22/2022 | Buy Now | 14.97% | Morgan Stanley | Matthew Harrison | $39 → $50 | Maintains | Overweight | Get Alert |
| 08/09/2022 | Buy Now | 24.17% | Stifel | Paul Matteis | $50 → $54 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | -37.92% | Mizuho | Graig Suvannavejh | $30 → $27 | Maintains | Neutral | Get Alert |
| 07/07/2022 | Buy Now | -31.02% | Mizuho | Graig Suvannavejh | → $30 | Initiates | → Neutral | Get Alert |
| 05/24/2022 | Buy Now | -54.01% | Goldman Sachs | Madhu Kumar | $28 → $20 | Maintains | Neutral | Get Alert |
| 02/15/2022 | Buy Now | -37.92% | Goldman Sachs | Madhu Kumar | → $27 | Initiates | → Neutral | Get Alert |
| 01/05/2022 | Buy Now | 14.97% | JP Morgan | Cory Kasimov | → $50 | Initiates | → Overweight | Get Alert |
| 12/16/2021 | Buy Now | 14.97% | HC Wainwright & Co. | Douglas Tsao | — | Initiates | → Buy | Get Alert |
| 09/07/2021 | Buy Now | -10.32% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Cerevel Therapeutics Hldg (CERE) stock?
The latest price target for Cerevel Therapeutics Hldg (NASDAQ:CERE) was reported by Mizuho on February 16, 2024. The analyst firm set a price target for $45.00 expecting CERE to rise to within 12 months (a possible 3.47% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?
The latest analyst rating for Cerevel Therapeutics Hldg (NASDAQ:CERE) was provided by Mizuho, and Cerevel Therapeutics Hldg maintained their neutral rating.
When was the last upgrade for Cerevel Therapeutics Hldg (CERE)?
The last upgrade for Cerevel Therapeutics Holdings Inc happened on May 4, 2023 when Wells Fargo raised their price target to $30. Wells Fargo previously had an equal-weight for Cerevel Therapeutics Holdings Inc.
When was the last downgrade for Cerevel Therapeutics Hldg (CERE)?
The last downgrade for Cerevel Therapeutics Holdings Inc happened on December 22, 2023 when Jefferies changed their price target from $40 to $45 for Cerevel Therapeutics Holdings Inc.
When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cerevel Therapeutics Hldg, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cerevel Therapeutics Hldg was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?
While ratings are subjective and will change, the latest Cerevel Therapeutics Hldg (CERE) rating was a maintained with a price target of $25.00 to $45.00. The current price Cerevel Therapeutics Hldg (CERE) is trading at is $43.49, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.